Table 6 Sensitivity analysis of the incremental cost effectiveness of pregabalin versus gabapentin in the treatment of painful diabetic neuropathy and post herpetic neuralgia
Parameter | Baseline | Sensitivity analysis | Cost per additional day with no or mild pain | Cost per QALY gained |
|---|---|---|---|---|
Gabapentin dose (mg) | 2400 | 1800 | 14 (8,19) | 23 786 (14266,33498) |
Gabapentin dose (mg) | 2400 | 1200 | 16 (9,24) | 30 241 (18086,44056) |
Costs considered | All healthcare costs | Medication cost only | 16 (14,18) | 25 683 (22812,29829) |
Pregabalin daily cost | 3.65 | ↑20% | 24 (18,34) | 39 063 (28704,54620) |
Pregabalin daily cost | 3.65 | ↓20% | 7 (2,14) | 11 075 (2944,23040) |
Weekly probability of PCP visit in relation to NeP | No/mild: 0.25 | ↑20% | 14 (8,20) | 21 025 (11592,30710) |
Moderate: 0.31 | ||||
Severe: 0.48 | ||||
Weekly probability of PCP visit in relation to NeP | No/mild: 0.25 | ↓20% | 13 (7,19) | 19 773 (10531,28687) |
Moderate: 0.31 | ||||
Severe: 0.48 | ||||
Health utility associated with pain severity | No/mild: 0.64 | ↑20% | 13 (9,18) | 17 017 (10296,23936) |
Moderate: 0.48 | ||||
Severe: 0.27 | ||||
Health utility associated with pain severity | No/mild: 0.64 | ↓20% | 14 (8,20) | 27 505 (15418,40596) |
Moderate: 0.48 | ||||
Severe: 0.27 |